Cited by 212Circular RNAs in diseasesMicroRNA in disease regulationCancer-related molecular mechanisms research

Synthetic circular RNA functions as a miR-21 sponge to suppress gastric carcinoma cell proliferation

Open access
Liu, Xi, Abraham, John M., Cheng, Yulan, Wang, Zhixiong, Wang, Zhe, Zhang, Guanjun, Ashktorab, Hassan, Smoot, Duane T. +6 more·2018·Molecular Therapy Nucleic Acids

Abstract

MicroRNA (miR) sponges containing miR binding sequences constitute a potentially powerful molecular therapeutic strategy. Recently, naturally occurring circular RNAs (circRNAs) were shown to function as efficient miR sponges in cancer cells. We hypothesized that synthetic circRNA sponges could achieve therapeutic loss-of-function targeted against specific miRs. Linear RNA molecules containing miR-21 binding sites were transcribed in vitro; after dephosphorylation and phosphorylation, circularization was achieved using 5'-3' end-ligation by T4 RNA ligase 1. circRNA stability was assessed using RNase R and fetal bovine serum. Competitive inhibition of miR-21 activity by a synthetic circRNA sponge was assessed using luciferase reporter, cell proliferation, and cell apoptosis assays in three gastric cancer cell lines. circRNA effects on downstream proteins were also delineated by Tandem Mass Tag (TMT) labeling (data available via ProteomeXchange identifier PRIDE: PXD008584), followed by western blotting. We conclude that artificial circRNA sponges resistant to nuclease digestion can be synthesized using simple enzymatic ligation steps. These sponges inhibit cancer cell proliferation and suppress the activity of miR-21 on downstream protein targets, including the cancer protein DAXX. In summary, synthetic circRNA sponges represent a simple, effective, convenient strategy for achieving targeted loss of miR function in vitro, with potential future therapeutic application in human patients.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.omtn.2018.09.010

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 34

  1. [1]Fitzmaurice C. Dicker D. Pain A. Hamavid H. Moradi-Lakeh M. MacIntyre M.F. Allen C. Hansen G. Woodbrook R. Wolfe C. Global Burden of Disease Cancer Collaboration The global burden of cancer 2013 JAMA Oncol. 1 2015 505 527 26181261 PMC4500822
  2. [3]Bartel D.P. MicroRNAs: target recognition and regulatory functions Cell 136 2009 215 233 19167326 PMC3794896
  3. [4]Ventura A. Jacks T. MicroRNAs and cancer: short RNAs go a long way Cell 136 2009 586 591 19239879 PMC3910108
  4. [5]Farazi T.A. Spitzer J.I. Morozov P. Tuschl T. miRNAs in human cancer J. Pathol. 223 2011 102 115 21125669 PMC3069496
  5. [6]Selaru F.M. Olaru A.V. Kan T. David S. Cheng Y. Mori Y. Yang J. Paun B. Jin Z. Agarwal R. MicroRNA-21 is overexpressed in human cholangiocarcinoma and regulates programmed cell death 4 and tissue inhibitor of metalloproteinase 3 Hepatology 49 2009 1595 1601 19296468 PMC3124086
  6. [7]Liu X. Meltzer S.J. Gastric cancer in the era of precision medicine Cell. Mol. Gastroenterol. Hepatol. 3 2017 348 358 28462377 PMC5404028
  7. [8]Ueda T. Volinia S. Okumura H. Shimizu M. Taccioli C. Rossi S. Alder H. Liu C.G. Oue N. Yasui W. Relation between microRNA expression and progression and prognosis of gastric cancer: a microRNA expression analysis Lancet Oncol. 11 2010 136 146 20022810 PMC4299826
  8. [9]Li X. Zhang Y. Zhang Y. Ding J. Wu K. Fan D. Survival prediction of gastric cancer by a seven-microRNA signature Gut 59 2010 579 585 19951901
  9. [10]Zhang Z. Li Z. Gao C. Chen P. Chen J. Liu W. Xiao S. Lu H. miR-21 plays a pivotal role in gastric cancer pathogenesis and progression Lab. Invest. 88 2008 1358 1366 18794849
  10. [11]Motoyama K. Inoue H. Mimori K. Tanaka F. Kojima K. Uetake H. Sugihara K. Mori M. Clinicopathological and prognostic significance of PDCD4 and microRNA-21 in human gastric cancer Int. J. Oncol. 36 2010 1089 1095 20372781
  11. [12]Ebert M.S. Neilson J.R. Sharp P.A. MicroRNA sponges: competitive inhibitors of small RNAs in mammalian cells Nat. Methods 4 2007 721 726 17694064 PMC3857099
  12. [13]Ma L. Young J. Prabhala H. Pan E. Mestdagh P. Muth D. Teruya-Feldstein J. Reinhardt F. Onder T.T. Valastyan S. miR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis Nat. Cell Biol. 12 2010 247 256 20173740 PMC2845545
  13. [14]Memczak S. Jens M. Elefsinioti A. Torti F. Krueger J. Rybak A. Maier L. Mackowiak S.D. Gregersen L.H. Munschauer M. Circular RNAs are a large class of animal RNAs with regulatory potency Nature 495 2013 333 338 23446348
  14. [16]Hansen T.B. Jensen T.I. Clausen B.H. Bramsen J.B. Finsen B. Damgaard C.K. Kjems J. Natural RNA circles function as efficient microRNA sponges Nature 495 2013 384 388 23446346
  15. [17]Chen L. Zhang S. Wu J. Cui J. Zhong L. Zeng L. Ge S. circRNA_100290 plays a role in oral cancer by functioning as a sponge of the miR-29 family Oncogene 36 2017 4551 4561 28368401 PMC5558096
  16. [18]Han D. Li J. Wang H. Su X. Hou J. Gu Y. Qian C. Lin Y. Liu X. Huang M. Circular RNA circMTO1 acts as the sponge of microRNA-9 to suppress hepatocellular carcinoma progression Hepatology 66 2017 1151 1164 28520103
  17. [20]Kan T. Sato F. Ito T. Matsumura N. David S. Cheng Y. Agarwal R. Paun B.C. Jin Z. Olaru A.V. The miR-106b-25 polycistron, activated by genomic amplification, functions as an oncogene by suppressing p21 and Bim Gastroenterology 136 2009 1689 1700 19422085 PMC2887605
  18. [21]Forbes S.A. Bindal N. Bamford S. Cole C. Kok C.Y. Beare D. Jia M. Shepherd R. Leung K. Menzies A. COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer Nucleic Acids Res. 39 2011 D945 D950 20952405 PMC3013785
  19. [24]Li Q. Wang X. Wu X. Rui Y. Liu W. Wang J. Wang X. Liou Y.C. Ye Z. Lin S.C. Daxx cooperates with the Axin/HIPK2/p53 complex to induce cell death Cancer Res. 67 2007 66 74 17210684
  20. [25]Ma X. Choudhury S.N. Hua X. Dai Z. Li Y. Interaction of the oncogenic miR-21 microRNA and the p53 tumor suppressor pathway Carcinogenesis 34 2013 1216 1223 23385064 PMC3670255
  21. [26]Tay F.C. Lim J.K. Zhu H. Hin L.C. Wang S. Using artificial microRNA sponges to achieve microRNA loss-of-function in cancer cells Adv. Drug Deliv. Rev. 81 2015 117 127 24859534
  22. [27]Song J.H. Meltzer S.J. MicroRNAs in pathogenesis, diagnosis, and treatment of gastroesophageal cancers Gastroenterology 143 2012 35 47.e2 22580099
  23. [28]Lin C.W. Chang Y.L. Chang Y.C. Lin J.C. Chen C.C. Pan S.H. Wu C.T. Chen H.Y. Yang S.C. Hong T.M. Yang P.C. MicroRNA-135b promotes lung cancer metastasis by regulating multiple targets in the Hippo pathway and LZTS1 Nat. Commun. 4 2013 1877 23695671
  24. [29]Weng W. Wei Q. Toden S. Yoshida K. Nagasaka T. Fujiwara T. Cai S. Qin H. Ma Y. Goel A. Circular RNA ciRS-7-A promising prognostic biomarker and a potential therapeutic target in colorectal cancer Clin. Cancer Res. 23 2017 3918 3928 28174233 PMC5511556
  25. [30]Hsiao K.Y. Lin Y.C. Gupta S.K. Chang N. Yen L. Sun H.S. Tsai S.J. Noncoding effects of circular RNA CCDC66 promote colon cancer growth and metastasis Cancer Res. 77 2017 2339 2350 28249903 PMC5910173
  26. [31]Yang W. Du W.W. Li X. Yee A.J. Yang B.B. Foxo3 activity promoted by non-coding effects of circular RNA and Foxo3 pseudogene in the inhibition of tumor growth and angiogenesis Oncogene 35 2016 3919 3931 26657152
  27. [32]Zheng Q. Bao C. Guo W. Li S. Chen J. Chen B. Luo Y. Lyu D. Li Y. Shi G. Circular RNA profiling reveals an abundant circHIPK3 that regulates cell growth by sponging multiple miRNAs Nat. Commun. 7 2016 11215 27050392 PMC4823868
  28. [33]Chen J. Li Y. Zheng Q. Bao C. He J. Chen B. Lyu D. Zheng B. Xu Y. Long Z. Circular RNA profile identifies circPVT1 as a proliferative factor and prognostic marker in gastric cancer Cancer Lett. 388 2017 208 219 27986464
  29. [34]Pan X. Wang Z.X. Wang R. MicroRNA-21: a novel therapeutic target in human cancer Cancer Biol. Ther. 10 2010 1224 1232 21139417
  30. [35]Kluiver J. Slezak-Prochazka I. Smigielska-Czepiel K. Halsema N. Kroesen B.J. van den Berg A. Generation of miRNA sponge constructs Methods 58 2012 113 117 22836127
  31. [36]Robinson M.D. McCarthy D.J. Smyth G.K. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data Bioinformatics 26 2010 139 140 19910308 PMC2796818
  32. [38]Gentner B. Schira G. Giustacchini A. Amendola M. Brown B.D. Ponzoni M. Naldini L. Stable knockdown of microRNA in vivo by lentiviral vectors Nat. Methods 6 2009 63 66 19043411
  33. [39]Heckman K.L. Pease L.R. Gene splicing and mutagenesis by PCR-driven overlap extension Nat. Protoc. 2 2007 924 932 17446874
  34. [40]Choung S. Kim Y.J. Kim S. Park H.O. Choi Y.C. Chemical modification of siRNAs to improve serum stability without loss of efficacy Biochem. Biophys. Res. Commun. 342 2006 919 927 16598842

Cited by

Sorted by citations

Authors
Liu, X., Abraham, J. M., Cheng, Y., Wang, Z., Wang, Z., Zhang, G., Ashktorab, H., Smoot, D. T., Cole, R. N., Boronina, T. N., DeVine, L. R., Talbot, C. C., Liu, Z., & Meltzer, S. J.
Affiliations
  • Johns Hopkins University (US)
  • First Affiliated Hospital of Xi'an Jiaotong University (CN)
  • Howard University (US)
  • Meharry Medical College (US)
Corresponding author
Meltzer, Stephen J.
Venue
Molecular Therapy Nucleic Acids
Publisher
Elsevier BV
Published
2018-12
Volume
13
Pages
312-321
ISSN
2162-2531 (ISSN-L)
OpenAlex
W2892938674
Cited by
212
References
5
Citations by year
2026: 10 · 2025: 24 · 2024: 29 · 2023: 17 · 2022: 44 · 2021: 30 · 2020: 34 · 2019: 24
FWCI
8.18
Type
journal article
Language
en
Open access
Locations
  • Molecular Therapy — Nucleic Acids (publishedVersion, cc-by-nc-nd)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
National Institutes of Health (CA190040, CA211457, DK118250)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Circular RNAs in diseases
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › MicroRNA in disease regulation
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer-related molecular mechanisms research
Keywords
microRNA sponge, gastric cancer, cell proliferation, DAXX, RNA circularization

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review